Surmodics to Present at Canaccord Genuity Medical Technologies and Diagnostics Forum
Webcast is Live on Thursday, November 9, at 9 a.m. (ET)
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Oct. 26, 2017--
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in
vitro diagnostic technologies to the healthcare industry, today
announced that Gary Maharaj, president and chief executive officer, and
Andy LaFrence, vice president of finance and information systems and
chief financial officer, will make a presentation to the investment
community at the Canaccord Genuity Medical Technologies and Diagnostics
Forum in New York City on Thursday, November 9, 2017, at 9 a.m. ET
(8 a.m. CT).
A live audio webcast of the presentation will be available by going to
the investor relations portion of the Company’s website at www.surmodics.com
and clicking on the webcast icon. The webcast will be archived on the
Company’s website for 90 days following the live presentation.
About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for
intravascular medical devices and a leading provider of chemical
components for in vitro diagnostic (IVD) tests and microarrays.
Following two recent acquisitions of Creagh Medical and NorMedix, the
Company is executing a key growth strategy for its medical device
business by expanding to offer total intravascular product solutions to
its medical device customers. The combination of proprietary surface
technologies, along with enhanced device design, development and
manufacturing capabilities, enables Surmodics to significantly increase
the value it offers with highly differentiated intravascular solutions
designed and engineered to meet the most demanding requirements. With
this focus on offering total solutions, Surmodics’ mission remains to
improve the detection and treatment of disease. Surmodics is
headquartered in Eden Prairie, Minnesota. For more information about the
company, visit www.surmodics.com.
The content of Surmodics’ website is not part of this press release or
part of any filings that the company makes with the SEC.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171026005293/en/
Source: Surmodics, Inc.
Andy LaFrence, 952-500-7000